

Check Your Body Mass Index (BMI)¹

Who is a candidate for the LAP-BAND AP™ Adjustable Gastric Banding System?

Adults who have a BMI:

- ≥ 40 or
- ≥ 35 with 1 or more severe obesity-related comorbidities

		Height (ft)									
		4'9"	4'11"	5'1"	5'3"	5'5"	5'7"	5'9"	5'11"	6'1"	6'3"
Weight (lbs)	154	33	31	29	27	26	24	23	22	20	19
	165	36	33	31	29	28	26	24	23	22	21
	176	38	36	33	31	29	28	26	25	23	22
	187	40	38	35	33	31	29	28	26	25	24
	198	43	40	37	35	33	31	29	28	26	25
	209	45	42	40	37	35	33	31	29	28	26
	220	48	44	42	39	37	35	33	31	29	28
	231	50	47	44	41	39	36	34	32	31	29
	243	52	49	46	43	40	38	36	34	32	30
	254	55	51	48	45	42	40	38	35	34	32
	265	57	53	50	47	44	42	39	37	35	33
	276	59	56	52	49	46	43	41	39	37	35
	287	62	58	54	51	48	45	42	40	38	36
	298	64	60	56	53	50	47	44	42	39	37
	309	67	62	58	55	51	48	46	43	41	39
	320	69	64	60	57	53	50	47	45	42	40
	331	71	67	62	59	55	52	49	46	44	42
	342	74	69	65	61	57	54	51	48	45	43
	353	76	71	67	63	59	55	52	49	47	44
	364	78	73	69	64	61	57	54	51	48	46
375	81	76	71	66	62	59	56	52	50	47	
386	83	78	73	68	64	61	57	54	51	48	
397	86	80	75	70	66	62	59	56	53	50	
408	88	82	77	72	68	64	60	57	54	51	
419	90	84	79	74	70	66	62	59	56	53	
430	93	87	81	76	72	67	64	60	57	54	
441	95	89	83	78	73	69	65	62	58	55	
452	98	91	85	80	75	71	67	63	60	57	
463	100	93	87	82	77	73	69	65	61	58	

Weight Category	BMI (kg/m ²)
Normal Weight	18.5-24.9
Overweight	25-29.9
Obesity	30-34.9
Severe Obesity	35-39.9
Morbid Obesity	≥ 40




© 2007 Allergan, Inc. Irvine, CA 92612
 ® and ™ Marks owned by Allergan, Inc.
 All rights reserved. M1403-03 10/07 RCW

Obesity in America—A Growing Concern


Morbid obesity is a serious disease associated with a number of life-threatening diseases that can be improved with sufficient weight loss. The LAP-BAND® System can help patients take control of their weight and their life.

Facts About Obesity in the United States

2005 Obesity Prevalence Rates²




Weight Gain Increases Risk for Type 2 Diabetes in Women³



- In women aged 30-55, a BMI ≥35 increases the risk of type 2 diabetes as much as 93 fold³
- When BMI exceeds 30, the relative risk of premature death increases by 50%⁴
- Morbid obesity increases the risk of many serious diseases and health conditions including, but not limited to, asthma, hypertension, type 2 diabetes, gastroesophageal reflux, and sleep apnea^{1,4}

Weight loss with the LAP-BAND® System may help improve or resolve comorbidities



The LAP-BAND® Adjustable Gastric Banding System procedure is a minimally invasive, adjustable, and reversible surgical treatment for obesity. It is a tool to help patients improve their health and enhance their quality of life.

Make sure your patients are educated about the risks of being obese and their surgical weight loss options.

References: 1. American Association of Clinical Endocrinologists/American College of Endocrinology Obesity Task Force. AAACE/ACE position statement on the prevention, diagnosis, and treatment of obesity. *Endocr Pract.* 1998;4:297-330. 2. Morbidity and Mortality Weekly Report Web site. State-specific prevalence of obesity among adults — United States, 2006;55:985-988. Available at: www.cdc.gov/MMWR/preview/mmwrhtml/mm5536a1.htm. Accessed January 17, 2007. 3. Colditz GA, Willett WC, Rostitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. *Ann Intern Med.* 1995;122:481-486. 4. US Department of Health and Human Services. *The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity.* Rockville, MD: US Department of Health and Human Services, Public Health Service, Office of the Surgeon General; 2001. 5. Dixon JB, Chapman L, O'Brien PE. Marked improvement in asthma after LAP-BAND surgery for morbid obesity. *Obes Surg.* 1999;9:385-389. 6. Dixon JB, O'Brien PE. Health outcomes of severely obese type 2 diabetic subjects 1 year after laparoscopic adjustable gastric banding. *Diabetes Care.* 2002;25:358-363. 7. Dixon JB, Schachter LM, O'Brien PE. Sleep disturbance and obesity: changes following surgically induced weight loss. *Arch Intern Med.* 2001;161:102-106. 8. Dixon JB, O'Brien PE. Gastroesophageal reflux in obesity: the effect of LAP-BAND placement. *Obes Surg.* 1999;9:527-531.

A BRIEF DESCRIPTION OF RELEVANT INDICATIONS FOR USE, CONTRAINDICATIONS, WARNINGS, AND ADVERSE EVENTS OF THE LAP-BAND® SYSTEM.

Indications: The LAP-BAND® System is indicated for use in weight reduction for severely obese patients with a Body Mass Index (BMI) of at least 40 or a BMI of at least 35 with one or more severe comorbid conditions, or those who are 100 lbs. or more over their estimated ideal weight.

Contraindications: The LAP-BAND® System is not recommended for non-adult patients, patients with conditions that may make them poor surgical candidates or increase the risk of poor results, who are unwilling or unable to comply with the required dietary restrictions, or who currently are or may be pregnant.

Warnings: The LAP-BAND® System is a long-term implant. Explant and replacement surgery may be required at some time. Patients who become pregnant or severely ill, or who

require more extensive nutrition may require deflation of their bands. Patients should not expect to lose weight as fast as gastric bypass patients, and band inflation should proceed in small increments. Anti-inflammatory agents, such as aspirin, should be used with caution and may contribute to an increased risk of band erosion.

Adverse Events: Placement of the LAP-BAND® System is major surgery and, as with any surgery, death can occur. Possible complications include the risks associated with the medications and methods used during surgery, the risks associated with any surgical procedure, and the patient's ability to tolerate a foreign object implanted in the body.

Band slippage, erosion and deflation, obstruction of the stomach, dilation of the esophagus, infection, or nausea

and vomiting may occur. Reoperation may be required.

Rapid weight loss may result in complications that may require additional surgery. Deflation of the band may alleviate excessively rapid weight loss or esophageal dilation.

Not all contraindications, warnings, or adverse events are included in this brief description. More detailed risk information is available at www.lapbandcentral.com or 1-800-624-4261.

 **LAP-BAND AP**
SYSTEM
Designed for Advanced Performance